Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 3/20 | 0.47 |
| ▸ | CCKBR | P32239 | 1/20 | 0.45 |
| ▸ | CALCRL | Q16602 | 15/20 | 0.43 |
| ▸ | RAMP1 | O60894 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9718390 | 0.83 | CCKBR (0.61) | CCKBR | |
| SCHEMBL7432000 | 0.83 | CCKBR (0.61) | CCKBR | |
| SCHEMBL3888484 | 0.77 | KCNH2 (0.59) | KCNH2CCKBRCALCRLRAMP1 | |
| SCHEMBL11472781 | 0.74 | LMNA (0.47) | KCNH2CCKBRCALCRL | |
| SCHEMBL3247608 | 0.73 | KCNH2 (0.57) | KCNH2CALCRLRAMP1 | |
| SCHEMBL7212287 | 0.72 | KCNH2 (0.51) | KCNH2CALCRLRAMP1 | |
| SCHEMBL3859605 | 0.71 | GABRP (0.61) | KCNH2CALCRLRAMP1 | |
| SCHEMBL1834474 | 0.71 | GABRP (0.61) | KCNH2CALCRLRAMP1 | |
| SCHEMBL3252899 | 0.70 | KCNH2 (0.38) | KCNH2CALCRLRAMP1 | |
| SCHEMBL3888483 | 0.69 | KCNH2 (0.37) | KCNH2CCKBRCALCRLRAMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1856100-B1 | CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2010-05-05 | — | — | EP | disclosed |
| US-7632832-B2 | CGRP receptor antagonists | MERCK & CO., INC. (US) | 2009-12-15 | — | — | US | disclosed |
| EP-1856100-A4 | CGRP RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 2009-04-15 | — | — | EP | disclosed |
| US-20080125413-A1 | Cgrp Receptor Antagonists | MERCK SHARP & DOHME LLC | 2008-05-29 | — | — | US | disclosed |
| EP-1856100-A2 | CGRP RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 2007-11-21 | — | — | EP | disclosed |
| WO-2006078554-A2 | CGRP RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2006-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125413-A1 | Cgrp Receptor Antagonists | CALCRL, NPY1R, CCKBR | KCNH2 117/4885CCKBR 3/4885CALCRL 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.